Table 4.
Average annualized cancer-attributable oral prescription drug costs (Medicare Part D) and SE for CRC patients diagnosed 2000–2013, SEER-Medicare*
| Patient characteristic | Mean (SE) | Mean (SE) | Mean (SE) | Mean (SE) |
|---|---|---|---|---|
| Site | ||||
| Overall | $429 (30) | $252 (13) | $1164 (55) | $201 (42) |
| Colon | $494 (35) | $315 (15) | $1197 (66) | $235 (47) |
| Rectum | $229 (58) | $77 (26) | $1087 (100) | $83 (96) |
| Age | ||||
| 65–69 | $548 (73) | $310 (34) | $2323 (170) | $14 (269) |
| 70–74 | $486 (77) | $283 (30) | $1886 (141) | −$60 (170) |
| 75–79 | $540 (63) | $222 (32) | $1393 (158) | $229 (140) |
| 80+ | $264 (40) | $222 (17) | $415 (59) | $258 (44) |
| Sex | ||||
| Male | $569 (51) | $349 (20) | $1706 (93) | $289 (71) |
| Female | $319 (36) | $178 (17) | $716 (64) | $140 (52) |
| Race | ||||
| White | $377 (33) | $207 (14) | $1052 (59) | $180 (46) |
| Black | $481 (110) | $406 (47) | $1079 (179) | $495 (133) |
| Other or unk | $758 (96) | $492 (45) | $2117 (207) | $47 (181) |
| Stage | ||||
| 0 | $561 (80) | $452 (38) | $2284 (432) | $572 (140) |
| I | $505 (64) | $349 (23) | $1103 (143) | $366 (76) |
| II | $36 (44) | $95 (22) | $752 (115) | $172 (73) |
| III | $421 (61) | $82 (27) | $1225 (107) | −$150 (97) |
| IV | $1023 (148) | $544 (110) | $1437 (107) | −$675 (239) |
| Part D | ||||
| No | — (—) | — (—) | — (—) | — (—) |
| Yes, not LIS | $341 (28) | $144 (13) | $1190 (64) | $42 (57) |
| Yes, LIS | $602 (64) | $512 (28) | $1144 (93) | $371 (61) |
| Prior cancer | ||||
| No | $308 (33) | $198 (14) | $1031 (63) | $102 (46) |
| Yes | $904 (69) | $545 (35) | $1619 (114) | $619 (105) |
| Zip code median income | ||||
| 0–$22 512 | $303 (53) | $180 (24) | $1049 (101) | $102 (79) |
| $22 513–$28 571 | $303 (53) | $172 (26) | $964 (104) | $90 (83) |
| $28 572–$36 332 | $500 (79) | $360 (31) | $1338 (119) | $282 (90) |
| $36 333+ | $656 (63) | $391 (26) | $1455 (137) | $434 (93) |
| Zip code college graduated | ||||
| 0–16.7% | $132 (49) | $114 (23) | $952 (97) | $60 (79) |
| 16.8–26.5% | $397 (56) | $178 (25) | $1077 (108) | $98 (79) |
| 26.6–41.3% | $546 (74) | $429 (31) | $1277 (129) | $396 (89) |
| 41.4%+ | $741 (70) | $397 (27) | $1534 (128) | $390 (101) |
| Diagnosis year | ||||
| 2007 | $377 (57) | $200 (31) | $604 (101) | $206 (99) |
| 2008 | $413 (65) | $203 (29) | $737 (117) | $131 (108) |
| 2009 | $601 (100) | $240 (32) | $553 (130) | $330 (111) |
| 2010 | $444 (81) | $283 (34) | $694 (130) | $156 (106) |
| 2011 | $421 (78) | $265 (33) | $637 (111) | $94 (114) |
| 2012 | $297 (88) | $230 (34) | $1563 (167) | $253 (110) |
| 2013 | $456 (81) | $310 (35) | $3103 (205) | $241 (119) |
CRC = colorectal cancer; EOL = end of life; LIS = Part D low-income subsidy; SE = standard error; SEER = SEER = Surveillance, Epidemiology, and End Results; unk = unknown. Cancer-attributable costs are calculated as the average monthly difference in costs between CRC cases minus their matched controls multiplied by 12 and inflated to 2014 US dollars. Medicare costs include Medicare payments and patient's responsibility. †Initial phase represents the first 12 months after diagnosis, the EOL is defined as the 12 months before death, and the continuing phase is the months between the initial and the EOL phase. ‡ZIP code median family income and ZIP code percentage college graduated cut-points represent the quartiles observed calculated using the observed values for all US ZIP codes.